WILMINGTON, N.C., Oct. 23 /PRNewswire-FirstCall/ -- PPD, Inc. today announced the opening of offices in Sydney, Australia; Copenhagen, Denmark; Lisbon, Portugal; and Lima, Peru; reflecting continued expansion of its Phase II-IV services in key therapeutic areas.
The four new offices broaden the company’s global footprint for delivering clinical services in response to increasing client demand. With an office in Melbourne, Sydney is PPD’s second location in Australia. Offices in Copenhagen, Lisbon and Lima establish PPD’s physical presence in those countries.
“With the biopharmaceutical industry increasingly relying on outsourcing, these new offices are important to our strategic growth in areas where there is high demand for our global experience and therapeutic expertise,” said Fred Eshelman, chief executive officer of PPD. “We will continue to execute our globalization strategy by positioning our people, systems and infrastructure in locations that meet the needs of our clients.”
PPD’s Sydney office is based at 1 Pacific Highway, North Sydney, and the Copenhagen office is at Regus South Harbour at Sluseholmen 2-4. The Lisbon office is at Avenida da Liberdade, 110-1, and the Lima office is located at the Centro Empresarial Real -- San Isidro Edificio Real Seis, Piso 7. For more information about PPD services provided at Sydney, Copenhagen and Lisbon, call +1 919 456 4402, and for Lima, call +1 910 558 6789.
PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 30 countries and more than 10,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions about the opening of new offices and our globalization strategy, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making those forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: economic conditions and outsourcing trends in the pharmaceutical, biotechnology and medical device industries and government-sponsored research sector; loss of or delay in large contracts; dependence on collaborative relationships; rapid technological advances that make our products and services less competitive; risks associated with acquisitions and investments, such as impairments; competition within the outsourcing industry; continued success in sales growth; the ability to attract and retain key personnel; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.
sueann.pentecost@rtp.ppdi.comstephen.smith@wilm.ppdi.com
CONTACT: Media, Sue Ann Pentecost, +1-919-456-5890,
sueann.pentecost@rtp.ppdi.com; or Analysts/Investors, Steve Smith,
+1-910-558-7585, stephen.smith@wilm.ppdi.com, both of PPD, Inc.
Web site: http://www.ppdi.com/
